Related Experiment Video

Updated: Oct 2, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K

Mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock

Ayman Al-Atta1, Mohammad Zaidan2, Ahmed Abdalwahab1,3

  • 1Department of Cardiology, Freeman Hospital, NE7 7DN Newcastle upon Tyne, UK.

Reviews in Cardiovascular Medicine
|March 1, 2022
PubMed

Insights

Patients with acute myocardial infarction and cardiogenic shock (CS) face poor outcomes. This review explores updated CS classification, pathophysiology, and mechanical circulatory support (MCS) evidence to improve patient care.

Area of Science:

  • Cardiology
  • Critical Care Medicine

Background:

  • Acute myocardial infarction (MI) complicated by cardiogenic shock (CS) carries a high mortality rate.
  • Recent decades show some improvement in CS mortality, but significant challenges remain.
  • Standard care involves shock protocols, including volume expansion, inotropes/vasopressors, and early revascularization.

Purpose of the Study:

  • To discuss emerging concepts in cardiogenic shock, including updated classification and pathophysiology.
  • To review recent evidence on the use and optimal timing of mechanical circulatory support (MCS) in CS patients.

Main Methods:

  • Literature review focusing on recent advancements in cardiogenic shock management.
  • Analysis of data regarding the efficacy and outcomes associated with mechanical circulatory support (MCS) devices.
  • Examination of studies on the timing of MCS initiation in patients with CS.

Main Results:

  • Mechanical circulatory support (MCS) devices show improved hemodynamic and metabolic profiles in CS patients.
  • Despite hemodynamic benefits, MCS has not consistently reduced adverse cardiovascular events.
  • Evidence on the optimal timing for initiating MCS in CS is still evolving.

Conclusions:

  • Understanding evolving CS classification and pathophysiology is crucial.
  • Further research is needed to translate MCS hemodynamic benefits into reduced adverse cardiovascular events.
  • Optimizing the timing of MCS initiation is key to improving outcomes for CS patients.

Keywords:
Cardiogenic shockECMOIABPImpella

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K
The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

22.4K

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
97
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
43
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
37
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47